California providers: Quest Diagnostics is proud to offer the GDSP cfDNA Panel as part of the California Prenatal Screening Program. Learn More →

Cervical cancer screening

cervical cancer

Cervical cancer screening and the COVID pandemic1-4

Cervical cancer is still a concern. The COVID-19 pandemic has reduced cervical cancer screening and associated cancer diagnoses—putting women’s lives at risk.

Screening visits went down during the pandemic. As a consequence, diagnoses are down, and patients may be under-screened.

Double-digit decline in cervical cancer diagnoses within 1 year of the start of the COVID-19 pandemic4

cervical cancer

cervical cancer

Make sure your patients ages 30-65 receive the best screening protection: co-testing.

What is co-testing?

The Pap test looks at actual cells to see if cancer is present or likely to occur. The HPV test detects the virus that causes most cervical cancers.

Co-testing with Pap and HPV together identifies more cases of cancer and precancer than either test alone.

Co-testing matters

In a recent Quest Diagnostics Health Trends® retrospective, longitudinal study, 1 in 5 women (22.5%) with cervical cancer would have been missed by screening with HPV alone.8

Guidelines support co-testing

Guidelines from leading health organizations, ACOG, USPSTF, and ASCCP continue to endorse co-testing as a Grade A level screening option in women ages 30-65.5-7

DOWNLOAD THE LATEST GUIDELINES

Latest Guidelines

Guidelines support co-testing

Guidelines from leading health organizations, ACOG, USPSTF, and ASCCP continue to endorse co-testing as a Grade A level screening option in women ages 30-65.5-7

Latest Guidelines

DOWNLOAD THE LATEST GUIDELINES

Co-testing matters

In a recent Quest Diagnostics Health Trends® retrospective, longitudinal study, 1 in 5 women (22.5%) with cervical cancer would have been missed by screening with HPV alone.8

Co-testing versus HPV alone

22.5% of cancers would not have been identified with HPV alone8

Data <12 months of cancer diagnosis

Co-testing vs HPV

Co-testing vs HPV

Co-testing versus Pap alone

11% of precancers would not have been identified with Pap alone8

Data <12 months of precancer diagnosis

Co-testing vs Pap

Co-testing vs Pap

Pap + HPV = Co-testing

Not all Pap tests are created equal

With our robust cervical cancer testing menu, you can rely on Pap testing from Quest Diagnostics to help you make a more informed diagnosis and treatment plan for your patients.

  • Quest evaluates more Paps and high-grade squamous intraepithelial lesions (HSILs) than any other lab
  • Normal Paps are rescreened at nearly 2x the minimum federal requirement for labs
  • All Paps from high-risk patients are double-screened
  • All abnormal Paps are reviewed by 1 or more pathologists
  • Our expert pathologists are available for consultation

While we offer a choice of Pap collection systems,
Quest Diagnostics recommends the ThinPrep® Pap test
due to its proven clinical performance.

59.7%
higher HSILs detected than conventional Pap testing9
59.7%
higher HSILs detected than conventional Pap testing9

Learn more

Thin prep

Aptima® HPV mRNA testing: excellent, similar sensitivity and better specificity vs HPV DNA testing

The Aptima® HPV mRNA assay identifies the presence and activity of high-risk HPV infections, allowing you to identify and focus on those women who most need your care.

Identification of the HPV types most associated with cervical cancer, including adenocarcinoma
Better specificity,10 which can minimize false positives11 and help reduce unnecessary invasive procedures
37%
Aptima HPV has been shown to reduce false positives by 37% vs Roche cobas® HPV12
24%
Aptima HPV has been shown to reduce false positives by 24% vs digene HC211
Identification of the HPV types most associated with cervical cancer, including adenocarcinoma
Better specificity,10 which can minimize false positives11 and help reduce unnecessary invasive procedures
37%
Aptima HPV has been shown to reduce false positives by 37% vs Roche cobas® HPV12
24%
Aptima HPV has been shown to reduce false positives by 24% vs digene HC211

Learn more

Give her the best screening: give her co-testing

Smart Codes make it easy to incorporate co-testing into your practice

Smart Codes: a solution from Quest to help you order the combination of an image-guided Pap, HPV test, and sexually transmitted infection (STI) testing appropriate for her age and risk factors.5-7

TEST CODE TEST NAME
91384

Image-Guided Pap with Age-Based Screening Protocols

91385

Image-Guided Pap with Age-Based Screening with CT/NG

91386

Image-Guided Pap with Age-Based Screening with CT/NG, Trichomonas

Learn more

Why co-testing?

Please see these important resources below.

Learn more about co-testing

DOWNLOAD BROCHURE 

Learn more about co-testing

DOWNLOAD BROCHURE 

Quest Diagnostics Health Trends® study

DOWNLOAD BROCHURE 

Quest Diagnostics Health Trends® study

DOWNLOAD BROCHURE 

Quest Diagnostics Health Trends® study

DOWNLOAD BROCHURE 

To access all testing options for cervical cancer screening, please visit our test directory

​Test codes may vary by location. Please contact your local laboratory for more information.

​References:

  1. Bakouny Z, Paciotti M, Schmidt AL, et al. Cancer screening tests and cancer diagnoses during the COVID-19 pandemic. JAMA Oncol. 2021;7(3):458-460. doi: 10.1001/jamaoncol.2020.7600
  2. Peters B, Pfaff C. The impact of COVID-19 on cervical, breast cancer screenings. Pharm Times. 2022;4(3):19-21.
  3. Miller MJ, Xu L, Qin J, et al. Impact of COVID-19 on Cervical Cancer Screening Rates Among Women Aged 21-65 Years in a Large Integrated Health Care System —Southern California, January 1-September 30, 2019, and January 1-September 30, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(4):109-113. doi:10.15585/mmwr.mm7004a1
  4. Kaufman HW, Chen Z, Niles JK, et al. Changes in newly identified cancer among US patients from before COVID-19 through the first full year of the pandemic. JAMA Netw Open. 2021;4(8):e2125681. doi:10.1001/jamanetworkopen.2021.25681
  5. US Preventive Services Task Force. Final recommendation statement: cervical cancer: screening. August 21,2018. Accessed July 1, 2022. https://uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening
  6. ASCCP. Screening Guidelines. 2020. Accessed July 1, 2022. https://www.asccp.org/screening-guidelines
  7. American College of Obstetricians and Gynecologists. Updated cervical cancer screening guidelines. Practice advisory. Updated April 2021. Accessed July 1, 2022. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines
  8. Kaufman HW, Alagia DP, Chen Z, et al. Contributions of liquid-based (Papanicolaou) cytology and human papillomavirus testing in co-testing for detection of cervical cancer and precancer in the United States. Am J Clin Pathol. 2020;154(4):510-516. doi:10.1093/ajcp/aqaa074
  9. ThinPrep® 2000 system [package insert]. MAN-02624-001 Rev. 004. Hologic, Inc.; 2017.
  10. Aptima HPV Assay (package insert) AW-10958 Rev. 002, 2015-02. Hologic, Inc.; 2017.
  11. Monsonego J, Hudgens MG, Zerat L, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer. 2011;129(3):691-701. doi:10.1002/ijc.25726
  12. Cuzick J, Cadman L, Mesher D, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108(4):908-913. doi:10.1038/bjc.2013.22